Regular follow-up appointments, typically every 36 months, allow your healthcare team to monitor your HbA1c, assess treatment response, and check for any adverse effects
Hopefully that clears up some of the confusionwithout creating more
Prior to that, the treatment of obesity has been predominantly limited to lifestyle interventions and bariatric surgery
The STEP 5 trial assessed the efficacy and safety of once-weekly subcutaneous semaglutide 2.4 mg versus placebo (both plus behavioral intervention) for long-term treatment of adults with obesity, or overweight with at least one weight-related comorbidity, without diabetes
H.KaminakaH.SanekataT.ShibaharaT.et al
Months 4 to 6: Steady Progress Dose climbs to 1.7 milligrams at week 13, then 2.4 milligrams at week 17